Elutia (ELUT) Preferred Stock Liabilities (2019 - 2020)

Elutia's (ELUT) quarterly Preferred Stock Liabilities came in at $56.6 million in Q3 2020, up 36.66% year-on-year from $41.4 million in Q4 2019, and up 26.05% quarter-over-quarter from $44.9 million in Q2 2020.

Elutia (ELUT) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends

Elutia has disclosed Preferred Stock Liabilities across 2 years of filings, most recently posting $56.6 million for Q3 2020.

  • Preferred Stock Liabilities for Q3 2020 came in at $56.6 million, up 36.66% year-over-year; the trailing twelve-month figure through Sep 2020 was $56.6 million (up 36.66% YoY), and the FY2019 annual result was $44.4 million, changed N/A from the prior year.
  • Preferred Stock Liabilities came in at $56.6 million for Q3 2020 at Elutia, up from $44.9 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $56.6 million in Q3 2020 to a low of $41.4 million in Q3 2019.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Abbott Laboratories 154.42 Bn 147.76 Bn 6.27 Bn -
2 Stryker 118.12 Bn 115.25 Bn 3.81 Bn -
3 Medtronic 101.72 Bn 93.55 Bn 5.76 Bn -
4 Boston Scientific 67.19 Bn 65.98 Bn 3.61 Bn -
5 Edwards Lifesciences 50.69 Bn 47.02 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.09 Bn 26.97 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.08 Bn 26.02 Bn 1.98 Bn -
9 Steris 19.80 Bn 19.37 Bn 697.10 Mn -
10 Elutia 45.15 Mn 16.66 Mn 1.80 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2020 56.59 Mn
Jun 30, 2020 44.90 Mn
Mar 31, 2020 44.90 Mn
Dec 31, 2019 44.45 Mn
Sep 30, 2019 41.41 Mn